Login to Your Account

Discounts Where It Counts

Optimer Hopes Less Is More For CDAD Antibiotic Dificid

By Brian Orelli
BioWorld Insight Contributing Writer

Monday, October 15, 2012

Optimer Pharmaceuticals Inc.'s Dificid (fidaxomicin), the first new product approved for Clostridium difficile-associated diarrhea (CDAD) in more than 25 years, has a superior rate of sustained clinical response through 25 days after the end of treatment compared to oral vancomycin. (See BioWorld Today, May 31, 2011.)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription